Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05181735 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 40 to 41
    • Eligibility criteria expanded, about 31 words
  2. Study sites: 38 to 40v9
  3. Site details revised at 4 of 38 sitesv8
  4. Primary completion date: May 19, 2027 to Dec 19, 2028
    • Study sites: 37 to 38
    • Study completion date: Nov 19, 2027 to Jun 19, 2029
    v7
  5. Study sites: 31 to 37v6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 3 of 31 sitesv5
  2. Site details revised at 5 of 31 sitesv4
  3. Study sites revised (31)v3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Feb 1, 2022 to May 18, 2022
    • Study sites: 29 to 31
    • Primary completion date: Feb 1, 2027 to May 19, 2027
    • Study completion date: Aug 1, 2027 to Nov 19, 2027
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
Trial Details
NCT Number NCT05181735
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: Celgene
Conditions
(from sponsor)		 MDS, Myelodysplastic Syndromes
Related terms Myelodysplastic Syndromes
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov